Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 15;10(1):2176.
doi: 10.1038/s41467-019-09976-3.

Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitis

Affiliations

Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitis

John A Lees et al. Nat Commun. .

Abstract

Streptococcus pneumoniae is a common nasopharyngeal colonizer, but can also cause life-threatening invasive diseases such as empyema, bacteremia and meningitis. Genetic variation of host and pathogen is known to play a role in invasive pneumococcal disease, though to what extent is unknown. In a genome-wide association study of human and pathogen we show that human variation explains almost half of variation in susceptibility to pneumococcal meningitis and one-third of variation in severity, identifying variants in CCDC33 associated with susceptibility. Pneumococcal genetic variation explains a large amount of invasive potential (70%), but has no effect on severity. Serotype alone is insufficient to explain invasiveness, suggesting other pneumococcal factors are involved in progression to invasive disease. We identify pneumococcal genes involved in invasiveness including pspC and zmpD, and perform a human-bacteria interaction analysis. These genes are potential candidates for the development of more broadly-acting pneumococcal vaccines.

PubMed Disclaimer

Conflict of interest statement

N.J.C. and S.D.B. were consultants for Antigen Discovery, Inc involved in the design of a proteome array for S. pneumoniae. E.A.M.S. reports grants from the pharmaceutical companies GlaxoSmithKline and Pfizer outside the submitted work. K.T. reports grants from Pfizer and consultancy fees from Pfizer paid to University Medical Centre Utrecht, both received outside the submitted work. A.L.W. received consulting fees for participation in advisory boards for Pfizer, outside the submitted work. D.v.d.B. received departmental honoraria for serving on a scientific advisory board for GlaxoSmithKline and InflaRx paid to the Amsterdam UMC, outside the submitted work. All the other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Overview of cohorts sequenced and associations performed. Left, host data; right, bacterial data; the centre represents samples with both host and pathogen sequence data. Samples in green are those collected from our MeninGene cohort that form the centre of this work. Owing to unbalanced case–control ratios, we show the effective sample size, specific numbers of cases and controls of human genotypes in Supplementary table 2
Fig. 2
Fig. 2
Burden of rare variation between invasive and carriage isolates, based on mapping and calling short variants against a single reference genome. Loss-of-function (LoF) are frameshift or nonsense mutations. a The site frequency spectrum (SFS) stratified by niche and by predicted consequence. Frequency has been normalized with respect to the number of samples in each population. b Histogram of Tajima’s D for all coding sequences in the genome, stratified by niche. c Boxplot of the number of rare variants per sample, stratified by niche and predicted consequence. Damaging mutations are LoF mutations and missense mutations predicted damaging by PROVEAN. Centre line is the median, box spans lower to upper quartiles. Whiskers show the outlier range, defined as being >1.5× the interquartile range above or below the lower and upper quartiles
Fig. 3
Fig. 3
Phylogenetic tree of all samples included in the pathogen genome-wide association study. Rings show metadata about samples, from inside to outside: phenotype (carriage or invasive); cohort (Netherlands or South Africa); common serotypes; patient age on a continuous scale from younger (white) to older (blue). Scale bar: 0.01 substitutions per site. An interactive version is available at https://microreact.org/project/Spn_GWAS/9eb0bd5d (project link https://microreact.org/project/Spn_GWAS)

References

    1. McIntyre PB, O’Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012;380:1703–1711. doi: 10.1016/S0140-6736(12)61187-8. - DOI - PubMed
    1. van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet. 2012;380:1693–1702. doi: 10.1016/S0140-6736(12)61186-6. - DOI - PubMed
    1. van de Beek Diederik, Brouwer Matthijs, Hasbun Rodrigo, Koedel Uwe, Whitney Cynthia G., Wijdicks Eelco. Community-acquired bacterial meningitis. Nature Reviews Disease Primers. 2016;2:16074. doi: 10.1038/nrdp.2016.74. - DOI - PubMed
    1. Bijlsma MW, et al. Community-acquired bacterial meningitis in adults in The Netherlands, 2006–14: a prospective cohort study. Lancet Infect. Dis. 2016;16:339–347. doi: 10.1016/S1473-3099(15)00430-2. - DOI - PubMed
    1. Brouwer MC, et al. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 2009;9:31–44. doi: 10.1016/S1473-3099(08)70261-5. - DOI - PubMed

Publication types